<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598205</url>
  </required_header>
  <id_info>
    <org_study_id>FGBBietti</org_study_id>
    <nct_id>NCT03598205</nct_id>
  </id_info>
  <brief_title>Curcumin and Intravitreal Dexamethasone in Diabetic Macular Edema</brief_title>
  <acronym>DIABEC</acronym>
  <official_title>Combination Therapy Based on Curcumin and Intravitreal Dexamethasone in Diabetic Macular Edema Treatment to Help the Antiedemigenous Effect of Intravitreal Dexamethasone in Subjects With Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione G.B. Bietti, IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione G.B. Bietti, IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to explore the effect of a curcumin formulation in combination to
      intravitreal dexamethasone therapy in patients with diabetic macular edema on morphological
      retinal characteristics and retreatment times.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with diagnosis of clinically significant diabetic macular edema, confirmed by
      fluorangiography and OCT, undergoing to intravitreal dexamethazone injection will be enrolled
      in the study.

      Enrollment will take place according to the inclusion/exclusion criteria set by the protocol.

      The enrolled patients will be randomized for the addition or not of the curcumin formulation
      (2 tablets/die for 6 months) to intravitreal therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Actual">June 10, 2019</completion_date>
  <primary_completion_date type="Actual">September 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference in CRT from baseline to 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>To explore the effect of curcumin formulation in addition to intravitreal dexamethasone therapy on OCT central retinal thickness after 6 months of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean difference in BCVA from baseline to 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>To explore the effect of curcumin formulation in addition to intravitreal dexamethasone therapy on BCVA after 6 months of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety: incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>To explore the safety of curcumin formulation (incidence of Treatment-Emergent Adverse Events ) in addition to intravitreal dexamethasone therapy after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retreatment times</measure>
    <time_frame>6 months</time_frame>
    <description>To explore the effect of curcumin formulation in addition to intravitreal dexamethasone therapy on retreatment times</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>DIABEC plus intravitreal dexamethazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:Curmin formulation (DIABEC) plus dexamethazone intravitreal injection. Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexamethazone intravitreal injection</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Intervention: dexamethazone intravitreal injection (0,7 mg) in PRN for diabetic macular edema treatment monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>DIABEC plus intravitreal dexamethazone</intervention_name>
    <description>Patients with diabetic macular edema undergoing to intravitreal dexamethazone will be randomized to curcumin formulation (DIABEC)</description>
    <arm_group_label>DIABEC plus intravitreal dexamethazone</arm_group_label>
    <other_name>Intravitreal dexamethazone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Patients with clinically significant diabetic macular edema in non-proliferative
             diabetic retinopathy, diagnosed by fluorangiography and OCT

          -  Naive patients

          -  Patients with clinically significant DME who have not been treated for more than 3
             months with anti-VEGF therapy and for more than 6 months with intravitreal injection
             of dexamethasone

          -  Central retinal thickness (CRT) at OCT&gt; 300 microns

          -  Best Corrected Visual Acuity (BCVA) with ETDRS tables at 4 meters not &lt;20/400

          -  Ability to provide written informed consent and follow the procedures of the study

        Exclusion Criteria:

          -  Retinal pathologies other than diabetic macular edema

          -  Proliferative diabetic retinopathy

          -  Opacities that limit the execution and interpretation of diagnostic tests

          -  Surgical interventions in the study eye in the 3 months prior to the start of
             treatment

          -  Pregnancy

          -  Feeding time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariacristina Parravano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione G.B. Bietti, IRCCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Università Humanitas Gavazzeni Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi Magna Graecia</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione G.B.Bietti-IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione G.B. Bietti, IRCCS</investigator_affiliation>
    <investigator_full_name>Mariacristina Parravano</investigator_full_name>
    <investigator_title>MD , Head RETINA UNIT</investigator_title>
  </responsible_party>
  <keyword>Therapy for diabetic macular edema</keyword>
  <keyword>Curcumin formulation (DIABEC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

